Ácido Gálico e seus derivados: candidatos promissores no combate às proteases virais do SARS-CoV-2

Mary´´elle Gobatto de Carvalho
OrcID

    Mary´´elle Gobatto de Carvalho

    Universidade Estadual de Campinas

    OrcID https://orcid.org/0000-0002-9818-7197

    Atualmente é pesquisadora de Pós Doutorado em um projeto vinculado à Empresa Brasileira de Pesquisa Agropecuária (EMBRAPA), desenvolvido na UNICAMP sob a supervisão da Dra. Ljubica Tasic. É Doutora em Química Orgânica pela Universidade Federal de Santa Catarina (UFSC), Mestre em Química Aplicada pela Universidade Estadual de Ponta Grossa (UEPG) e Bacharel em Química Industrial pela Universidade Tecnológica Federal do Paraná (UTFPR). É também especialista na área de Ensino de Química e Ciências. Sua expertise é na área de Síntese Orgânica, com ênfase em síntese de compostos bioativos e no desenvolvimento de metodologias sintéticas. Possui experiência em ensaios in vitro e citotoxicidade da protease Mpro do SARS-CoV-2 e poligalacturonases e em expressão de proteínas heterólogas de fungos.Seu interesse é na área de Química Medicinal.

Palavras-chave

ácido gálico
SARS-CoV-2
inibidores de proteases

Resumo

A pandemia da COVID-19, causada pelo SARS-CoV-2, destacou a importância da busca por novas abordagens terapêuticas, especialmente frente à rápida disseminação do vírus, à limitação de tratamentos eficazes e ao surgimento de novas variantes. O SARS-CoV-2 utiliza mecanismos de entrada celular mediados pela proteína Spike (S) e, após infecção, depende da ação de proteases virais essenciais — como a Mpro (protease principal) e PLpro (protease tipo papaína) — para sua replicação. Esses alvos se tornaram estratégicos para o desenvolvimento de novos fármacos antivirais. Neste contexto, produtos naturais e seus derivados, como o ácido gálico (AG), emergem como alternativas promissoras, por serem amplamente reconhecido por suas propriedades antioxidantes, anti-inflamatórias e antivirais. Este artigo de revisão explora os mecanismos de replicação das proteases do SARS-CoV-2 e discute o potencial terapêutico do AG e seus derivados, como candidatos promissores a inibidores virais contra as proteases do SARS-CoV-2. Os dados significativos foram coletados de diferentes bancos de dados (PubMed, Scopus, Science Direct e Web os Science), usando palavras chaves como ácido gálico, SARS CoV-2 e inibidores de proteases. Estudos in sílico e in vitro tem demonstrado que o AG e seus derivados podem atuar como inibidores potenciais das proteases Mpro e PLpro do SARS-CoV-2.

Referências

  1. Silva SM. Fatores de virulência microbianos e terapias emergentes. S586f. Organizadores: Barbosa AV, Silva SM, Silva FHS, Assunção MAS, Anjos FBR. São José dos Pinhais: Latin American Publicações, 2022. 354 p. ISBN: 978-65-996545-0-3. Disponível em: [https://www.researchgate.net/profile/Francisco-Silva-98/publication/359969282_Fatores_de_virulencia_microbianos_e_terapias_emergentes/links/6259b0e19be52845a906029f/Fatores-de-virulencia-microbianos-e-terapias-emergentes.pdf].
  2. Organização Pan-Americana da Saúde. Módulos de Princípios de Epidemiologia para o Controle de Enfermidades (OPAN/OMS). Módulo 2: Saúde e doença na população / Organização Pan-Americana da Saúde. Brasília: Organização Pan-Americana da Saúde. Ministério da Saúde, 2010. 48 p.: il. 7 volumes. ISBN 978-85-7967-020-6. Disponível em: [https://iris.paho.org/handle/10665.2/54407?show=full].
  3. Lemos ERS, Villar LM, Leon LAA, et al. T674t. Tópicos em virologia. ― Rio de Janeiro. Editora Fiocruz, 2023. 7 MB: il. color; tab. (Coleção Bio) ISBN: 978-65-5708-151-8. Disponível em: [https://books.scielo.org/id/5bhdb/pdf/lemos-9786557082119.pdf].
  4. Hoenen T, Groseth A. Virus-Host Cell Interactions. Cells. 2022 Feb 25; 11(5): 804. Disponível em: [https://www.mdpi.com/2073-4409/11/5/804].
  5. Klasse PJ, Bron R, Marsh M. Mechanisms of enveloped virus entry into animal cells. Adv Drug Deliv Rev. 1998 Oct 5; 34(1): 65-91. Disponível em: [https://pubmed.ncbi.nlm.nih.gov/10837671/].
  6. Villanueva RA, Rouillé Y, Dubuisson J. Interactions between virus proteins and host cell membranes during the viral life cycle. Int Rev Cytol. 2005; 245: 171-244. Disponível em: [https://pubmed.ncbi.nlm.nih.gov/16125548/].
  7. Schatzmayr HG, Cabral MC. A virologia no Estado do Rio de Janeiro: uma visão global. 2a Edição - Rio de Janeiro: FIOCRUZ, 2012. 176 p, 111p. 172 – 175. Disponível em: [https://www.ioc.fiocruz.br/sites/default/files/Livro_Virologia_nova_edicao.pdf].
  8. Louten J. Virus Replication. Essential Human. Virology. 2016; 49–70. Disponível em: [https://pmc.ncbi.nlm.nih.gov/articles/PMC7149683/].
  9. Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010 Jul; 10(7): 514-26. Disponível em: [https://www.nature.com/articles/nri2802].
  10. Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2018; 14(Suppl 2): 49. Disponível em: [https://aacijournal.biomedcentral.com/articles/10.1186/s13223-018-0278-1].
  11. Chappell JD, Dermody T. S.134 - Biology of Viruses and Viral Diseases. Editor(s): Bennett JE, Dolin R, Blaser MJ, Mandell, Douglas and Bennett's. Principles and Practice of Infectious Diseases (Eighth Edition), W.B. Saunders, 2015, Pages 1681-1693.e4. ISBN 9781455748013. Disponível em: [https://doi.org/10.1016/B978-1-4557-4801-3.00134-X]
  12. Seventer JMVS, Hochberg N. Principles of Infectious Diseases: Transmission, Diagnosis, Prevention, and Control. Editor(s): Stella R. Quah, International Encyclopedia of Public Health (Second Edition). Academic Press. 2017, Pages 22-39. ISBN 9780128037089. Disponível em: [https://doi.org/10.1016/B978-0-12-803678-5.00516-6].
  13. Zanella JRC. Zoonoses emergentes e reemergentes e sua importância para saúde e produção animal. Pesq Agropec Bras [online]. 2016; 51(05): 510-519. Disponível em: [https://doi.org/10.1590/S0100-204X2016000500011].
  14. Engering A, Hogerwerf L, Slingenbergh J. Pathogen–host environment interplay and disease emergence. Emerg Microb Infec. 2013; 2(1): 1-7. Disponível em: [https://doi.org/10.1038/emi.2013.5].
  15. Piret J, Boivin G. Pandemics Throughout History. Front Microbiol. 2021 Jan 15; 11: 631736. Disponível em: [https://pubmed.ncbi.nlm.nih.gov/33584597/].
  16. Baker RE, Mahmud AS, Miller IF, et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022; 20: 193–205. Disponível em: [https://doi.org/10.1038/s41579021-00639-z].
  17. Elkhatib WF, Abdelkareem SS, Khalaf W, et al. Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting. Virol J. 2022; 19: 167. Disponível em: [https://doi.org/10.1186/s12985-022-01902-2].
  18. Organização Pan-Americana da Saúde Módulos de Princípios de Epidemiologia para o Controle de Enfermidades (OPAN/OMS). Influenza, SARS-CoV-2, RSV and other Respiratory Viroses. [acesso em: 10 set]. 2023]. Disponível em: [https://www.paho.org/en/topics/influenza-sars-cov-2-rsvand-other-respiratory-viruses].
  19. Barrero CAB, Beam KS, Bernardini LB, Ramos EGC, Davenport PE, et al. COVID-19: neonatal–perinatal perspectives. J Perinatol. 2021; 41: 940–951. Disponível em: [https://doi.org/10.1038/s41372-020-00874-x].
  20. Harapan H, Itoh N, Yufika A, Winardi W, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020 May; 13(5): 667-673. Disponível em: [https://doi.org/10.1016/j.jiph.2020.03.019].
  21. Haghani M, Bliemer MCJ, Goerlandt F, Li J. The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review. Saf Sci. 2020 Sep; 129: 104806. Disponível em: [https://doi.org/10.1016/j.ssci.2020.104806].
  22. Painel Coronavírus. [acesso em: set 2025]. Disponível em: [https://covid.saude.gov.br/].
  23. Pal M, Berhanu G, Desalegn C, KandI V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020 Mar 26; 12(3): e7423. Disponível em: [https://doi.org/10.7759/cureus.7423].
  24. Hognon C, Bignon E, Monari A, Marazzi M, Garcia IC. Revealing the Molecular Interactions between Human ACE2 and the Receptor Binding Domain of the SARS-CoV-2 Wild-Type, Alpha and Delta Variants. Int J Mol Sci. 2023; 24: 2517. Disponível em: [https://doi.org/10.3390/ijms24032517].
  25. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein. Viruses. 2012; 4: 1011-1033. Disponível em: [https://doi.org/10.3390/v4061011].
  26. Dhama K, Khan S, Tiwari R, Sircar S, et al. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020 Jun 24; 33(4): e00028-20. Disponível em: [https://doi.org/10.1128/CMR.00028-20].
  27. Zhang J, Xiao T, Cai Y, Chen B. Structure of SARS-CoV-2 spike protein. Curr Opin Virol. 2021 Oct; 50: 173-182. Disponível em: [https://doi.org/10.1016/j.coviro.2021.08.010].
  28. Tran A, Kervin TA, Overduin M. Multifaceted membrane binding head of the SARS-CoV-2 spike protein. Curr Res Struct Biol. 2022 May 16; 4: 146-157. Disponível em: [https://doi.org/10.1016/j.crstbi.2022.05.001].
  29. Wang H, Zhao T, Yang S, et al. Reactive force field-based molecular dynamics simulation of the interaction between plasma reactive oxygen species and the receptor-binding domain of the spike protein in the capsid protein of SARS-CoV-2. J Phys D: Appl Phys. 55 095401. Disponível em: [https://iopscience.iop.org/article/10.1088/1361-6463/ac360e].
  30. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Sci. (New York, N.Y.). 2020; 367(6485): 1444-1448. Disponível em: [https://doi.org/10.1126/science.abb2762].
  31. Hu Q, Xiong Y, Zhu G, et al. The SARS-CoV-2 main protease (Mpro): Structure, and emerging therapies 19. MedComm. 2022; 3: e151. Disponível em: [https://doi.org/10.1002/mco2.151].
  32. Li X, Song Y. Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. Europ J Medic Chem. 2023; 260: 115772. Disponível em: [https://doi.org/10.1016/j.ejmech.2023.115772].
  33. World Health Organization (WHO). COVID-19 Cases, World. [acesso em: 02 mai. 2023]. Disponível em: [https://covid19.who.int/].
  34. Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. Am J Respir Crit Care Med. 2020 Sep 1; 202(5): 651-659. Disponível em: [https://doi.org/10.1164/rccm.202004-1263PP].
  35. Emrani J, Ahmed M, Jeffers-francis L, Teleha JC, et al. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. J Biol Macromol. 2021 Dec 15; 193(PtB): 1249-1273. Disponível em: [https://doi.org/10.1016/j.ijbiomac.2021.10.172].
  36. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol. 2004; 2(2): 109-22. Disponível em: [https://doi.org/10.1038/nrmicro817].
  37. Más V, Melero JA. Entry of Enveloped Viruses into Host Cells: Membrane Fusion. In: Mateu M. (eds) Structure and Physics of Viruses. Subcellular Biochemistry. 2013; 68: 467. Springer, Dordrecht. Disponível em: [https://doi.org/10.1007/978-94-007-6552-8_16].
  38. Shang J, Wan Y, Luo C, Ye G, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA. 2020, 26; 117(21): 11727-11734. Disponível em: [https://doi.org/10.1073/pnas.2003138117].
  39. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel corona virus spike protein. J Clin Pathol, 2020, Jul;73(7):366-369. Disponível em: [https://doi.org/10.1136/jclinpath-2020-206658].
  40. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4): 562-569. Disponível em: [https://doi.org/10.1038/s41564-020-0688-y].
  41. Örd M, Faustova I, Loog M. The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS CoV. Sci Rep 10. 2020, 16944. Disponível em: [https://doi.org/10.1038/s41598-020-74101-0].
  42. Huang Y, Yang C, Xu X, Xu W, Liu S. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID 19. Acta Pharmacol Sin. 2020; 41: 1141–1149. Disponível em: [https://doi.org/10.1038/s41401-020-0485-4].
  43. Chinchar VG. Replication of Viruses. Encyclop Virology. 1999: 1471–8. Disponível em: [https://doi.org/10.1006/rwvi.1999.0245].
  44. Pišlar A, Mitrović A, Sabotič J, Fonović PU, Nanut MP, et al. The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors. PLoS Pathog. 2020; 16(11): e1009013. Disponível em: [https://doi.org/10.1371/journal.ppat.1009013].
  45. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel T. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 2021; 19: 155–170. Disponível em: [https://doi.org/10.1038/s41579-020-00468-6].
  46. Qamar MT, Ul ASM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharmac Anal. 1 ago. 2020; 10(4): 313. Disponível em: [https://doi.org/10.1016/j.jpha.2020.03.009].
  47. Yan L, Zhang Y, Ge J, Zheng L, Gao Y, et al. Architecture of a SARS CoV-2 mini replication and transcription complex. Nat Commun. 2020 Nov 18; 11(1): 5874. Disponível em: [https://doi.org/10.1038/s41467-020-19770-1].
  48. Pluskota-karwatka D, Hoffmann M, Barciszewski J. Reducing SARS-CoV-2 pathological protein activity with small molecules. J Pharmac Anal. 2021; 11(4): 383-397. ISSN 2095-1779. Disponível em: [https://doi.org/10.1016/j.jpha.2021.03.012].
  49. Saville JW, Berezuk, AM, Srivastava SS, Subramaniam S. Three-Dimensional Visualization of Viral Structure, Entry, and Replication Underlying the Spread of SARS-CoV-2. Chem Ver. 2022; 122(17): 14066–14084. Disponível em: [https://doi.org/10.1021/acs.chemrev.1c01062].
  50. NoorI R, Sardar M. An outlook on potential protein targets of COVID-19 as a druggable site. Mol Biol Rep. 2022; 49: 10729–10748. Disponível em: [https://doi.org/10.1007/s11033-022 07724-3].
  51. Le K, Kannappan S, Kim T, Lee, JH, Lee H, Kim KK. Structural understanding of SARS-CoV-2 virus entry to host cells. Front Mol Biosci. 2023 Nov 2; 10: 1288686. Disponível em: [https://doi.org/10.3389/fmolb.2023.1288686].
  52. Rocha LPB, Alves JVO, Aguiar IFS, et al. Uso de plantas medicinais: Histórico e relevância. Res Society Develop. 2021; 10(10): e44101018282. (CC BY 4.0) | ISSN 2525-3409. Disponível em: [http://dx.doi.org/10.33448/rsd-v10i10.18282].
  53. Dar RA, Shahnawaz M, Rasool S, Qazi PH. Natural product medicines: A literature update. J Phytopharmacol. 2017; 6(6): 340 342. ISSN 2320-480X.
  54. Carneiro DM. Ayuerveda – Saúde e Longevidade na Tradição Milenar da Índia. Editora Pensamento. 2009. ISBN: 9788531516153, 8531516153.
  55. Organização Mundial da Saúde - OMS. Gabinete do Ministério da Saúde. Portaria Nº 849, de 27 de mar de 2017. [acesso em: 22 set. 2023]. Disponível em: [https://bvsms.saude.gov.br/bvs/saudelegis/gm/2017/prt0849_28_03_2017.html].
  56. Wright GD. Unlocking the potential of natural products in drug Discovery. Microbial Biotechnol. 2019. 12(1): 55–57. Disponível em: [https://doi.org/10.1111/1751-7915.13351].
  57. Dzobo K. The Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery. Compr Pharmacol. 2022; 408–22. Disponível em: [https://doi.org/10.1016/B978-0-12 820472-6.00041-4].
  58. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. fev. 2016; 79: 629−661. Disponível em: [https://doi.org/10.1021/acs.jnatprod.5b01055v].
  59. Veeresham C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res. 2012 Oct; 3(4): 200-1. Disponível em: [https://doi.org/10.4103/2231-4040.104709].
  60. Leite PM, Camargos LM, Castilho RO. Recent progess in phytotherapy: A Brazilian perspective. Europ J Integr Medic. 2021; 41: 101270. Disponível em: [https://doi.org/10.1016/j.eujim.2020.101270].
  61. Yuan H, Ma Q, Ye L, Piao G. A Medicina Tradicional e a Medicina Moderna a partir de Produtos Naturais. Molecules. 2016; 21: 559. Disponível em: [https://doi.org/10.3390/molecules21050559].
  62. Dias DA, Urban S, Roessner UTE. A Historical Overview of Natural Products in Drug Discovery. Metabolites. 2012; 2: 303-336. Disponível em: [https://doi.org/10.3390/metabo2020303].
  63. Ganjhu RKumar, Mudgal PP, Maity H, Dowarha D, et al. Herbal plants and plant preparations as remedial approach for viral diseases. Virus Disease. Dez 2015; 26: 225–236. Disponível em: [https://doi.org/10.1007/s13337-015-0276-6].
  64. Liu C, Zhou Q, Li Y, Garner LV, et al. Research and development on therapeutic agents and vaccines for Covid-19 and related human coronavirus diseases. ACS Cent Sci. mar. 2020; 6: 315−331. Disponível em: [https://doi.org/10.1021/acscentsci.0c00272v].
  65. Prasansuklab A, Theerasri A, Rangsinth P, et al. Anti COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. J Trad Complement Medic. 2021; 11(2): 144–157. Disponível em: [https://doi.org/10.1016/j.jtcme.2020.12.001].
  66. Rakib A, Nain Z, Sami AS, Mahmud S, Islam A, et al. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation. Brief Bioinformat. March 2021; 22(2): 1476–1498. Disponível em: [https://doi.org/10.1093/bib/bbab045].
  67. FDA. [acesso em: 11 mai. 2023]. Disponível em: [https://www.fda.gov/consumers/consumer-updates/know-yourtreatment-options-covid19].
  68. Tregoning J.S, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, et al. Vaccines for COVID-19. Clinic Experim Immunol. 2020; 202(2): 162- 192. Disponível em: [https://doi.org/10.1111/cei.13517].
  69. Academia Brasileira de Ciências (ABC). Nobel de medicina vai para cientistas que possibilitaram vacinas contra a COVID-19. [acesso em: 16 out. 2023]. Disponível em: [http://www.abc.org.br/2023/10/02/nobel-de-medicina-vai-para-cientistas-que-possibilitaram as-vacinas-contra-a-covid-19/].
  70. Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atlurl P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J Clin Med Res. 2021 Jun; 13(6): 317-325. Disponível em: [https://doi.org/10.14740/jocmr4518].
  71. Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021; 22: 757-773. Disponível em: [https://doi.org/10.1038/s41576-021-00408-x].
  72. Lombardino JG, Lowe JA. The role of the medicinal chemist in drug discovery — then and now. Nat Rev Drug Discov 2024; 3: 853–862. Disponível em: [https://doi.org/10.1038/nrd1523].
  73. Nadendla RR. Molecular modeling: A powerful tool for drug design and molecular docking. Reson. 2004; 9: 51–60. Disponível em: [https://doi.org/10.1007/BF02834015].
  74. Durrant JD, Mccammon J. Molecular dynamics simulations and drug discovery. BMC Biol 2011; 9: 71. Disponível em: [https://doi.org/10.1186/1741-7007-9-71].
  75. Aminpour M, Montemagno C, TuszynskI JA. An Overview of Molecular Modeling for Drug Discovery with Specific Illustrative Examples of Applications. Molecules. 2019 Apr; 30; 24(9): 1693. Disponível em: [https://doi.org/10.3390/molecules24091693].
  76. Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023 Aug 17; 13(1): 13398. Disponível em: [https://doi.org/10.1038/s41598-023-40160-2].
  77. AdelusI T, Oyedele AQK, Boyenle IA, Ogunlana AT, Adeyemi RO, et al. Molecular modeling in drug Discovery. Informatics in Medicine Unlocked. 2022; 29: 100880. Disponível em: [https://doi.org/10.1016/j.imu.2022.100880].
  78. Pushkaran AC, En PN, Melge AR, Puthiyedath R, Mohan GC. Searching Phytochemical based Medication for SARS-CoV 2 infection by Molecular docking models towards Spike glycoprotein and Main Protease. RSC Av. 2021; 11: 12003-12014. Disponível em: [https://doi.org/10.1039/D0RA10458B].
  79. Morris GM, Lim-wilby M. Molecular docking. Methods Mol Biol. 2008; 443: 365-82. Disponível em: [https://doi.org/10.1007/978-1-59745-177-2_19].
  80. Rogers DM, Agarwal R, Vermaas JV, et al. SARS-CoV2 billion compound docking. Sci Data. 2023; 10: 173. Disponível em: [https://doi.org/10.1038/s41597-023-01984-9].
  81. BadhanI B, Sharma N, Kakkar R. Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications. RSC Adv. 2015; 5: 27540-27557. Disponível em: [https://doi.org/10.1039/C5RA01911G]
  82. Bhuia MDS, Rahaman MDM, Islam T, et al. Neurobiological effects of gallic acid: current perspectives. Chin Med. 2023; 18: 27. Disponível em: [https://doi.org/10.1186/s13020 023-00735-7].
  83. Fernandes FHA, Salgado HRN. Gallic Acid: Review of the Methods of Determination and Quantification. Critical Rev Analytic Chem. 2016; 46(3): 257-265. Disponível em: [https://doi.org/10.1080/10408347.2015.1095064].
  84. Baraskar K, Thakur P, Shrivastava R, Shrivastava VK.Therapeutic Role of Phytophenol Gallic Acid for the Cure of COVID-19. Pathogen Endoc Metab Imm Disord - Drug Targets. 2023; 23(4). Disponível em: [https://dx.doi.org/10.2174/1871530322666220829141401].
  85. Badhani B, Kakkar R. Influence of intrinsic and extrinsic factors on the antiradical activity of Gallic acid: a theoretical study. Struct Chem. 2018; 29: 359–373. Disponível em: [https://doi.org/10.1007/s11224-017-1033-9].
  86. LeopoldinI M, Pitarch IP, Russo N, Toscano M. Structure, Conformation, and Electronic Properties of Apigenin, Luteolin, and Taxifolin Antioxidants. A First Principle Theoretical Study. J Physic Chem A. 2004; 108(1): 92–96. Disponível em: [https://doi.org/10.1021/jp035901j].
  87. Sroka Z, Cisowski W. Hydrogen peroxide scavenging, antioxidant and anti-radical activity of some phenolic acids. Food Chem Toxicol. 2003; 41(6): 753-758. [https://doi.org/10.1016/s0278-6915(02)00329-0].
  88. Zahrani NA, Al ES, Reda M, Asiri M. Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review. Europ J Medic Chem. 2020; 204: 112609. Disponível em: [https://doi.org/10.1016/j.ejmech.2020.112609]
  89. Tirado-kulieva VA, Hernández-martínez E, Choque R, Tania J. Phenolic compounds versus SARS-CoV-2: An update on the main findings against COVID-19. Heliyon. 2022; 8(9): e10702. Disponível em: [https://doi.org/10.1016/j.heliyon.2022.e10702].
  90. Umar HI, Siraj B, Ajayi A, Jimoh TO, Prosper Obed. Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. J Genet Eng Biotechnol. 2021; 19(1): 16. Disponível em: [https://doi.org/10.1186/s43141-021-00120-7].
  91. Hadidi M, Liñán-Atero R, Tarahi M, Christodoulou MC, Aghababaei F. The Potential Health Benefits of Gallic Acid: Therapeutic and Food Applications. Antioxidants (Basel). 2024 Aug 18; 13(8): 1001. Disponível em: [https://doi.org/10.3390/antiox13081001].
  92. Alhyari D, Qinna NA, Sheldrake HM, Kantamneni S, Ghanem BY, Paluch KJ. Antioxidant, Anti-Inflammatory, and Oral Bioavailability of Novel Sulfonamide Derivatives of Gallic Acid. Antioxidants. 2025; 14: 374. Disponível em: [https://doi.org/10.3390/antiox14040374].
  93. Aghasafari P, George U, Pidaparti R. A review of inflammatory mechanism in airway diseases. Inflamm Res. 2019; 68: 59–74. Disponível em: [https://doi.org/10.1007/s00011-018-1191-2].
  94. Chavda VP, Bezbaruah R, Ahmed N, Alom S, Bhattacharjee B, Nalla LV, et al. Proinflammatory Cytokines in Chronic Respiratory Diseases and Their Management. Cells. 2025: 14: 400. Disponível em: [https://doi.org/10.3390/cells14060400].
  95. Alhyari D, Qinna NA, Sheldrake HM, Kantamneni S, Ghanem BY, Paluch KJ. Antioxidant, Anti-Inflammatory, and Oral Bioavailability of Novel Sulfonamide Derivatives of Gallic Acid. Antioxidants. 2025; 14: 374. Disponível em: [https://doi.org/10.3390/antiox14040374].
  96. Aatl HY, IsmaiL A, Rateb ME, Aboulmagd AM, Hassan HM, Hetta MH. Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking. Plants (Basel). 2022 Sep 26; 11(19): 2521. Disponível em: [https://doi.org/10.3390/plants11192521].
  97. Khan T, Khan MA, Mashwanl ZUR, Ullah N, Nadhman A. Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites. Biocatal Agric Biotechnol. 2021 Jan; 31: 101890. Disponível em: [https://doi.org/10.1016/j.bcab.2020.101890].
  98. Yushu G, Miaomiao L, Bart LS, Garry WB, Ronald JQ. Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7. ACS Pharmacol Translat Sci. 2023; 6(4): 578-586. Disponível em: [https://doi.org/10.1021/acsptsci.2c00225].
  99. Souza GB, Pontes CLM, Costa GO, et al. Inhibitory Effects of Mangifera indica Secondary Metabolites and Their Synthetic Derivatives against SARS-CoV-2 Mpro and NS2B/NS3 (ZIKV and DENV-2). ACS Omega. 2024; 9(44): 44624-44638. Disponível em: [https://doi.org/10.1021/acsomega.4c07148].
  100. Carvalho MAG, Souza GB, Tizziani T, et al. Synthesis, in vitro and in silico evaluation of gallamide and selenogallamide derivatives as inhibitors of the SARS-CoV-2 main protease. Arch Pharm. 2024; 357: e2400253. Disponível em: [https://doi.org/10.1002/ardp.202400253].
PDF
HTML
XML
Salvar em favoritos

Autor(es)

Métricas

  • Artigo visto 22 vez(es)

Como Citar

1.
Ácido Gálico e seus derivados: candidatos promissores no combate às proteases virais do SARS-CoV-2. Rev Fitos [Internet]. 4º de maio de 2026 [citado 6º de maio de 2026];20:e1932. Disponível em: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1932
Crossref
Scopus
Google Scholar
Europe PMC
Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2026 Revista Fitos

Informe um erro